ALK
Os inibidores de ALK são compostos que especificamente visam e inibem a quinase do linfoma anaplásico (ALK), uma tirosina quinase receptora envolvida no desenvolvimento e progressão de certos cânceres, incluindo o câncer de pulmão de células não pequenas e o neuroblastoma. Ao inibir ALK, esses compostos bloqueiam vias de sinalização que promovem o crescimento e a sobrevivência das células tumorais. Na CymitQuimica, oferecemos inibidores de ALK para apoiar sua pesquisa em oncologia, terapias direcionadas contra o câncer e transdução de sinal.
Foram encontrados 146 produtos para "ALK".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
DA-0157
CAS:DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.Fórmula:C31H43BrN7O2PCor e Forma:SolidPeso molecular:656.597ALK ligand-Linker Conjugate 1
CAS:ALK ligand-Linker Conjugate 1 is an ALK ligand-connector conjugate used for the synthesis of PROTACALK degrader-4.Fórmula:C36H45N5O3Cor e Forma:SolidPeso molecular:595.77WZH-15-125
CAS:WZH-15-125 is a potent ALK inhibitor capable of overcoming resistance, particularly with complex ALK mutations. It exhibits an IC50 of 101.7 nM against the highly recalcitrant Lorlatinib-resistant G1202R/L1196M mutation. Additionally, WZH-15-125 can serve as a PROTAC target protein ligand for synthesizing PROTACWZH-17-002. This compound is applicable in non-small cell lung cancer research.Fórmula:C33H45BrN8O5SCor e Forma:SolidPeso molecular:745.73W23-1006
CAS:W23-1006 is a selective covalent ALKBH5 inhibitor. By targeting the C200 residue to increase m6A levels, it suppresses growth and metastasis in TNBC models, utilized in research for RNA methylation and breast cancer therapy.Fórmula:C17H12BrN3O5Cor e Forma:Brown SolidPeso molecular:418.2Zotizalkib
CAS:TPX-0131: potent, selective, CNS-ready, oral ALK inhibitor (WT IC50: 1.4nM, G1202R/L1196M IC50: 0.3nM) with robust antitumor effects.Fórmula:C21H20F3N5O3Pureza:98.7%Cor e Forma:SolidPeso molecular:447.41Ref: TM-T9414
1mg114,00€5mg268,00€1mL*10mM (DMSO)303,00€10mg439,00€25mg879,00€50mg1.395,00€100mg1.873,00€AZ12601011
CAS:AZ12601011 is a TGFBR1 kinase inhibitor that inhibits the growth of breast tumors.Fórmula:C19H15N5Pureza:98.81%Cor e Forma:SolidPeso molecular:313.36Ref: TM-T10426
1mg94,00€5mg222,00€1mL*10mM (DMSO)245,00€10mg356,00€25mg690,00€50mg1.035,00€100mg1.431,00€
